z-logo
open-access-imgOpen Access
Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall
Author(s) -
Xinyu Gui,
Huiping Li,
Gonghua Song,
Bin Shao,
Hanfang Jiang
Publication year - 2018
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000013410
Subject(s) - medicine , bevacizumab , triple negative breast cancer , breast cancer , metastasis , lesion , chemotherapy , oncology , radiology , cancer , surgery
Rationale: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC. Patient concerns: We reported a 49-year-old woman presenting with a giant breast tumor. Diagnoses: Stage IV TNBC with chest wall metastasis. Interventions: The patient underwent long-term use of bevacizumab combined with chemotherapy. Outcomes: The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed. Lessons: Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here